JPWO2022192536A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022192536A5 JPWO2022192536A5 JP2023555206A JP2023555206A JPWO2022192536A5 JP WO2022192536 A5 JPWO2022192536 A5 JP WO2022192536A5 JP 2023555206 A JP2023555206 A JP 2023555206A JP 2023555206 A JP2023555206 A JP 2023555206A JP WO2022192536 A5 JPWO2022192536 A5 JP WO2022192536A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- abatacept
- aldesleukin
- administered
- units
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163159919P | 2021-03-11 | 2021-03-11 | |
| US63/159,919 | 2021-03-11 | ||
| US202163225846P | 2021-07-26 | 2021-07-26 | |
| US63/225,846 | 2021-07-26 | ||
| US202263310839P | 2022-02-16 | 2022-02-16 | |
| US63/310,839 | 2022-02-16 | ||
| PCT/US2022/019748 WO2022192536A1 (en) | 2021-03-11 | 2022-03-10 | Methods and compositions for treatment of disease |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024509911A JP2024509911A (ja) | 2024-03-05 |
| JPWO2022192536A5 true JPWO2022192536A5 (https=) | 2025-06-05 |
| JP2024509911A5 JP2024509911A5 (https=) | 2025-06-05 |
Family
ID=83228307
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023555206A Pending JP2024509911A (ja) | 2021-03-11 | 2022-03-10 | 疾患の治療のための方法及び組成物 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240148827A1 (https=) |
| EP (1) | EP4304624A4 (https=) |
| JP (1) | JP2024509911A (https=) |
| KR (1) | KR20230169147A (https=) |
| AU (1) | AU2022235091A1 (https=) |
| CA (1) | CA3211627A1 (https=) |
| MX (1) | MX2023010455A (https=) |
| WO (1) | WO2022192536A1 (https=) |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040022787A1 (en) * | 2000-07-03 | 2004-02-05 | Robert Cohen | Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID |
| EP1878440A1 (en) * | 2006-07-13 | 2008-01-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for increasing the efficiency of therapeutic antibodies using gamma delta cell activator compounds |
| WO2008127298A2 (en) * | 2006-10-24 | 2008-10-23 | Subroto Chatterjee | Staphylococcal enterotoxin b peptide compositions and methods of use |
| US9044459B2 (en) * | 2008-12-05 | 2015-06-02 | Als Therapy Development Institute | Method for the treatment of neurodegenerative diseases |
| EP2367849B1 (en) * | 2008-12-05 | 2017-11-01 | ALS Therapy Development Institute | Method for the treatment of neurodegenerative diseases |
| CN102573500A (zh) * | 2009-08-06 | 2012-07-11 | 纽拉尔图斯制药公司 | 巨噬细胞相关疾病的治疗 |
| PL3053932T3 (pl) * | 2010-02-19 | 2021-03-08 | Xencor, Inc. | Nowe immunoadhezyny CTLA4-IG |
| KR102220006B1 (ko) * | 2011-03-11 | 2021-02-24 | 아시스땅스 퍼블리끄-오삐또 드 빠리 | 자가면역 - 관련 또는 염증성 장애를 치료하기 위한 저용량 ｉｌ２ 의 용도 |
| EP2734232B1 (en) * | 2011-07-19 | 2017-11-01 | Philogen S.p.A. | Sequential anti-ctla4 and targeted il-2 therapy |
| WO2013041029A1 (en) * | 2011-09-23 | 2013-03-28 | Igenimed Pharmaceuticals Inc. | Novel soluble ctla4 variants |
| US20140044675A1 (en) * | 2012-08-10 | 2014-02-13 | Roche Glycart Ag | Interleukin-2 fusion proteins and uses thereof |
| WO2014206899A1 (en) * | 2013-06-25 | 2014-12-31 | Icm (Institut Du Cerveau Et De La Moelle Épinière) | Boosting treg cells for treating alzheimer disease and related disorders |
| US20170233485A1 (en) * | 2014-08-18 | 2017-08-17 | Biogen Ma Inc. | Anti-cd40 antibodies and uses thereof |
| EP3192805A1 (en) * | 2016-01-15 | 2017-07-19 | Humanitas Mirasole S.p.A. | Inhibitors of t cell activation or stimulation and uses thereof |
| JP7181862B2 (ja) * | 2016-10-18 | 2022-12-01 | リージェンツ オブ ザ ユニバーシティ オブ ミネソタ | 腫瘍浸潤リンパ球および治療の方法 |
| US11077172B2 (en) * | 2016-11-08 | 2021-08-03 | Delinia, Inc. | IL-2 variants for the treatment of psoriasis |
| CA3103603A1 (en) * | 2018-06-13 | 2019-12-19 | Akron Biotechnology, LLC. | Method to prepare therapeutically active aldesleukin highly stable in liquid pharmaceutical compositions |
| JP2022510377A (ja) * | 2018-12-03 | 2022-01-26 | デルマタ・セラピューティクス，エルエルシー | 状態の処置のための組成物 |
| CN113795271A (zh) * | 2019-03-08 | 2021-12-14 | 森德治疗公司 | 与irgd共施用以治疗癌症的低剂量细胞因子 |
| CN109999179A (zh) * | 2019-05-08 | 2019-07-12 | 山东省分析测试中心 | 低剂量白介素2用于制备治疗阿尔茨海默病药物中的应用 |
-
2022
- 2022-03-10 WO PCT/US2022/019748 patent/WO2022192536A1/en not_active Ceased
- 2022-03-10 MX MX2023010455A patent/MX2023010455A/es unknown
- 2022-03-10 US US18/280,632 patent/US20240148827A1/en active Pending
- 2022-03-10 CA CA3211627A patent/CA3211627A1/en active Pending
- 2022-03-10 AU AU2022235091A patent/AU2022235091A1/en active Pending
- 2022-03-10 EP EP22767990.9A patent/EP4304624A4/en active Pending
- 2022-03-10 JP JP2023555206A patent/JP2024509911A/ja active Pending
- 2022-03-10 KR KR1020237034557A patent/KR20230169147A/ko active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2653569C (en) | S1p receptor modulators for treating multiple sclerosis | |
| US6623736B2 (en) | Interleukin antagonists for the treatment of neurological, retinal and muscular disorders | |
| RU2013139651A (ru) | Новые соединения, влияющие на пищевое поведение | |
| JP2010518079A5 (https=) | ||
| EP0647137A4 (en) | GLYCINE RECEPTOR ANTAGONISTS AND THEIR USE. | |
| US6471961B1 (en) | Interleukin antagonists for the treatment of neurological, retinal and muscular disorders | |
| JP2004524278A5 (https=) | ||
| EP1499335A2 (en) | Chimeric hybrid analgesics | |
| JP2024102205A5 (https=) | ||
| RU2014101207A (ru) | Новые показания к применению при лечении антителами против il-1-бета | |
| IL287470B1 (en) | Derivatives of 6-methyl-6,1-dihydro-7H-pyrrolo[3,2-c]pyridin-7-one or of an acceptable pharmaceutical salt thereof and pharmaceutical preparations containing them. | |
| JP2020516607A5 (https=) | ||
| JPS61145121A (ja) | ジペプタイド誘導体を含有する、筋萎縮性側索硬化症を治療するための薬剤 | |
| EP1183047A2 (de) | Proteinenthaltende pharmazeutische zubereitung | |
| Steiger et al. | The clinical use of apomorphine in Parkinson's disease | |
| JP2019533004A (ja) | ｈＧＨ融合タンパク質を含有する、成長ホルモン欠乏症を治療するための医薬組成物 | |
| ES2917882T3 (es) | Tratamiento de esclerosis múltiple (MS) con Campath-1H | |
| JP2019530741A5 (https=) | ||
| JPWO2022192536A5 (https=) | ||
| JP2022501364A5 (https=) | ||
| EP0652755B1 (en) | Therapeutic use of phosphoryl-l-serine-n-acyl-sphingosine | |
| EP3416677B1 (en) | Pharmaceutical composition comprising recombinant hgh for the treatment of growth hormone deficiency | |
| JP2005529152A5 (https=) | ||
| JP2005511563A (ja) | チモシンα１ペプチドを投与する方法 | |
| KR102745928B1 (ko) | 혈액뇌장벽을 통과 가능한 폴리펩티드 |